Loading…
← CockpitCompetitor Analysis › AKTS Aktis Oncology, Inc.Open in the cockpit ↗

Aktis Oncology, Inc.AKTSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Develops alpha-emitting radiopharmaceutical (radioligand) therapies that deliver targeted radiation directly to tumors.

Momentum weak 27
Mkt cap
$895M
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$5.75M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
138 days
5 Apr 2027
Close · USD$16.10
1D-1.3%
1W-5.5%
1M+0.1%
3M-32.9%
6M-15.4%
YTDn/a
1Yn/a
ATR %6.2%
52w lowhigh52.9% off high

What Aktis Oncology does

Develops alpha-emitting radiopharmaceutical (radioligand) therapies that deliver targeted radiation directly to tumors.

Has no product on sale and earns nothing from customers, so development is funded by money raised from investors and potentially partners. Its value rests on clinical results for one family of cancer drugs.

Products and services

  • Alpha-emitter radioligand pipeline

Where it sits in the supply chain

  • Biopharma R&D
  • Radioligand/radiopharmaceutical drug…
  • Targeted alpha-emitter cancer therapy

What could go right

  • Growing radiopharmaceutical oncology category
  • Partnership/licensing interest from big pharma

What could go wrong

  • Complex isotope supply chain/manufacturing risk
  • Early-stage pipeline, binary trial risk

Moat: narrow (IP / patents, process know-how). Radiopharmaceutical manufacturing and isotope supply-chain know-how are hard for new entrants to build.

Headquarters: Boston, Massachusetts, US · Founded: 2019 · Employees: 79

Named competitors

Aktis Oncology at a glance

Size Aktis Oncology (AKTS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $895M, the 2298th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.10 on 18 Nov 2026.

Performance Over six months the shares fell 15.4%, against -24.5% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 19 in its peer set.

Growth Revenue grew 336.9% over the last twelve months (peer median +9.2%); the operating margin is -837.5% (peer median 7.1%).

Valuation It trades at 33.4× enterprise value to sales against a peer median of 3.8× (2nd most expensive of 17).

Short interest Short interest is 8.2% of the free float (30 Oct 2026).

Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026AKTS 84Peer median 77
Six months, rebased to 100: Aktis Oncology against the median of its 20 peers (local-currency closes).

Aktis Oncology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$12.4M$6.50M$1.49M$0
Revenue growth—+337%——
Gross profit$9.22M$4.17M-$88,000-$1.12M
EBITDA-$101M-$72.4M-$50.5M-$33.7M
Net income-$87.5M-$63.7M-$44.0M-$28.6M
Free cash flown/a-$73.7M$11.9M-$33.8M
Capital expendituren/a$9.58M$2.86M$3.76M
Total debt$10.8M$11.5M$12.0M$13.4M

Quarterly statements and history in the cockpit →

Aktis Oncology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%0005976885532595IMTXMLTX1795300401039200SANOFICONRPHARM0061206007716881774521CRVS600252069620086450AKTS6-month return →1-month return →
Up and to the right = strong over both horizons. Aktis Oncology is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×20×40×60×0005976885532595IMTX1795039200SANOFICONRPHARMAKTSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aktis Oncology is the large dot.

Aktis Oncology competitors and peer comparison

Head to head with its named competitors (AKTS vs NOVN.SW vs AZN.L vs BMY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Aktis Oncology AKTS$895M-15%+337%-837%33.4×n/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%

How Aktis Oncology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aktis Oncology against its 20 peers (data as of 18 Nov 2026)
MeasureAKTSPeer medianRank in peer set
1-month return+0.1%-9.3%5th highest of 21
6-month return-15.4%-24.5%8th highest of 19
Distance from 52-week high-52.9%-44.1%5th lowest of 21
Revenue growth (TTM)+336.9%+9.2%3rd highest of 18
Operating margin-837.5%7.1%lowest of 18
EV / Sales33.4×3.8×2nd most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%

Questions

Who are Aktis Oncology's main competitors?
Named competitors: Novartis (Pluvicto) (NOVN.SW), AstraZeneca (Fusion Pharmaceuticals) (AZN.L), Bristol Myers Squibb (RayzeBio) (BMY). The cockpit's measured peer set (industry) also includes Northeast Pharmaceutical (000597.SZ), Sichuan Huiyu Pharmaceutical (688553.SS), Latigo Biotherapeutics (LTGO), Genfleet Therapeutics (Shanghai) (2595.HK), Immatics (IMTX), MoonLake Immunotherapeutics (MLTX).
Is Aktis Oncology expensive compared with its peers?
On ev / sales it trades at 33.4× against a peer median of 3.8×, 2nd most expensive of 17 in its peer set.
How has Aktis Oncology stock performed?
Over six months to 18 Nov 2026 the shares returned -15.4% against -24.5% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.